Acridinium ester labeled protein compound as well as preparation method and application thereof

By adding termination buffer and centrifugation steps to the preparation of acridinium ester labeled protein complex, the problem of hydrolysis and high background value of acridinium ester system at high pH is solved, the sensitivity and stability of the detection are improved, and the The labeling efficiency of the antibody and the repetition of the experiment.

CN118914537APending Publication Date: 2024-11-08CHONGQING XINSAIYA BIOTECHNOLOGY CO LTD
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202411077967.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-07
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The existing acridinyl ester chemiluminescence system is prone to hydrolysis under high pH conditions, resulting in reduced stability, affecting antibody labeling efficiency and experimental stability, and at the same time, there are problems of high background values ​​and non-specific reactions.

Method used

Using a preparation method of acridinium ester labeled protein complex, the protein to be labeled is mixed with the acridinium ester group marker and the termination buffer is added for purification, and the supernatant is centrifuged to remove impurities, reduce the background value and By nonspecific reaction, the prepared acridinium ester-labeled protein complex has high sensitivity and repeatability.

Benefits of technology

It realizes low background signal value and high precision, the background signal value is less than 0.01, the CV value is less than 1%, the detection sensitivity is high, and the repeatability is good. After 7 days of heating in a 37℃ water bath, the signal retention rate reaches more than 90%, and the stability is better.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004982896490000081
    Figure BDA0004982896490000081
  • Figure BDA0004982896490000091
    Figure BDA0004982896490000091
  • Figure BDA0004982896490000111
    Figure BDA0004982896490000111
Patent Text Reader

Abstract

The invention belongs to the technical field of protein detection, and particularly relates to an acridinium ester labeled protein compound as well as a preparation method and application thereof. The preparation method of the acridinium ester labeled protein compound comprises the following steps: (1) mixing and reacting to-be-labeled protein and an acridinium ester group marker to obtain a first reaction solution; (2) adding a termination buffer solution into the first reaction solution, and carrying out a mixed reaction to obtain a second reaction solution; and (3) purifying the second reaction liquid, and centrifuging to take supernate, namely the acridinium ester labeled protein compound. The acridinium ester labeled antibody compound prepared by the preparation method is high in detection sensitivity, good in repeatability and excellent in stability.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of protein detection, and in particular relates to an acridinium ester labeled protein complex and a preparation method and application thereof. Background Art

[0002] Chemiluminescent immunoassay technology is one of the main technologies in immunological testing at present. It is a new type of labeled immunoassay technology that combines chemiluminescent analysis technology and immune response technology to detect various trace antigens, antibodies, haptens, drugs and hormones. It has the advantages of high degree of automation, good specificity, short detection time, high sensitivity and wide detection range. It is widely used in the field of modern medical testing.

[0003] There are many common chemiluminescence systems, among which the systems used as detection devices and means of clinical analysis and determination mainly include the following three categories: luminol chemiluminescence system, ruthenium bipyridine electrochemiluminescence system and acridinium ester chemiluminescence system. Among them, the luminol system is easily affected by environmental pH, temperature and other factors due to the participation of enzymes; the ruthenium bipyridine system has high requirements for instrument performance and strict requirements for cleaning conditions; compared with other chemiluminescence systems, the acridinium ester chemiluminescence system has the advantages of simple labeling process, low background, high sensitivity and short luminescence time, and has been widely used in in vitro immunodiagnosis.

[0004] In the existing acridinium ester chemiluminescence system, when the pH value of the labeling buffer is greater than 4.8, acridinium ester and its complex are easily hydrolyzed to reduce their stability, that is, the higher the pH value, the higher the degree of hydrolysis, and the lower the stability, thereby affecting the labeling efficiency of the antibody and the stability of the antibody in subsequent experiments; at the same time, during the labeling process, the reaction system contains acridinium ester that is not coupled to the antibody, resulting in abnormal conditions such as high reaction background value, high nonspecific reaction, and poor repeatability. Summary of the invention

[0005] The present invention develops a method for preparing an acridinium ester chemiluminescent system (acridinium ester labeled protein complex), which can reduce reaction background value and nonspecific reaction, and the prepared acridinium ester labeled protein complex has excellent detection sensitivity and repeatability.

[0006] In order to achieve the above object, the present invention can adopt the following technical solutions:

[0007] On the one hand, the present invention provides a method for preparing an acridinium ester-labeled protein complex, which comprises: (1) mixing a protein to be labeled and an acridinium ester group label to obtain a first reaction solution; (2) adding a stop buffer to the first reaction solution to obtain a second reaction solution; (3) purifying the second reaction solution, centrifuging and obtaining a supernatant, which is the acridinium ester-labeled protein complex.

[0008] Preferably, the above preparation method satisfies one or more combinations of the following conditions:

[0009] (a) In step (1), the acridinium ester group label is selected from acridinium ester or acridinium sulfonamide;

[0010] (b) in step (1), the protein to be labeled is a labeled protein diluted with a labeling buffer, and the labeling buffer is selected from one or more combinations of a phosphate solution, a carbonate solution, an acetate buffer, and a citrate buffer;

[0011] (c) In step (1), the protein to be labeled is a labeled protein diluted with a labeling buffer, and the concentration of the labeling buffer is 0.01 mol / L-0.03 mol / L;

[0012] (d) In step (1), the protein to be labeled is a labeled protein diluted with a labeling buffer, and the pH of the labeling buffer is 4-6;

[0013] (e) In step (1), the protein to be labeled is total immunoglobulin E antibody;

[0014] (f) In step (1), the concentration of the protein to be labeled is 0.5 mg / mL-1.5 mg / mL;

[0015] (g) In step (1), the molar ratio of the protein to be labeled to the acridinium ester group label is 1:(10-100);

[0016] (h) In step (2), the stop buffer is a lysine solution;

[0017] (i) In step (2), the mass of the termination buffer is ≥ 10 times the mass of the protein to be labeled.

[0018] Preferably, the above preparation method satisfies one or more combinations of the following conditions:

[0019] In step (1), the labeling buffer is a citrate buffer; or

[0020] In step (1), the concentration of the labeling buffer is 0.02 mol / L; or

[0021] In step (1), the pH of the labeling buffer is 4.5; or

[0022] In step (1), the concentration of the protein to be labeled is 1 mg / mL; or

[0023] In step (1), the molar ratio of the protein to be labeled to the acridinium ester is 1:20; or

[0024] In step (2), the concentration of the lysine solution is ≥10 mg / L.

[0025] Preferably, the above preparation method satisfies one or more combinations of the following conditions:

[0026] (a) In step (1), the mixing reaction comprises: shaking the reaction at 2°C-8°C in the dark for 1.5h-2.5h;

[0027] (b) In step (2), the mixing reaction comprises: shaking the reaction at 2°C-8°C in the dark for 20min-30min;

[0028] (c) in step (3), purification includes purification by elution using a desalting column;

[0029] (d) in step (3), purification includes purification by elution using a desalting column, and the eluent is PBS buffer;

[0030] (e) in step (3), purification includes purification by elution using a desalting column, wherein the eluent is a PBS buffer having a concentration of 0.01 mol / L-0.03 mol / L;

[0031] (f) In step (3), the centrifugal speed is 14500 rpm-15500 rpm;

[0032] (g) In step (3), the centrifugation temperature is 3°C-5°C;

[0033] (h) In step (3), the centrifugation time is 15 min-25 min.

[0034] Preferably, the above preparation method satisfies one or more combinations of the following conditions:

[0035] In step (1), the mixing reaction includes shaking the reaction at 5° C. in the dark for 2 h; or

[0036] In step (2), the mixing reaction comprises: shaking the reaction at 5° C. in the dark for 25 min; or

[0037] In step (3), the concentration of PBS buffer is 0.02 mol / L; or

[0038] In step (3), the centrifugal speed is 15000 rpm; or

[0039] In step (3), the centrifugation temperature is 4°C; or

[0040] In step (3), the centrifugation time is 20 min. or

[0041] Preferably, the preparation method further comprises mixing the supernatant with a protein diluent for storage.

[0042] Preferably, in the above preparation method, the volume proportion of the protein diluent is ≥30%.

[0043] Another aspect of the present invention provides an acridinium ester labeled protein complex prepared by the preparation method of the present invention.

[0044] In another aspect, the present invention provides a use of the acridinium ester-labeled protein complex of the present invention in detecting antigens / antibodies.

[0045] Preferably, the above application includes one of the following applications:

[0046] (a) Application of acridinium ester labeled antibodies as labeled antibodies in double antibody sandwich method for antigen determination;

[0047] (b) Application of acridinium ester labeled antigen as competitive antigen in competitive antigen / antibody determination.

[0048] The beneficial effects of the present invention include at least:

[0049] (1) The method for preparing the acridinium ester-labeled antibody complex provided by the present invention reduces the background value interference of impurities by adding a centrifugation step. The background signal value and precision CV value of the prepared acridinium ester-labeled antibody complex are both low, the background signal value is low (the blank limit is less than 0.01), and the CV value is less than 1%. That is, the acridinium ester-labeled antibody complex in the present invention has high detection sensitivity and good repeatability.

[0050] (2) In the preparation method of the acridinium ester-labeled antibody complex provided by the present invention, a labeling buffer with a pH of 4-6 is selected, so that the prepared acridinium ester-labeled antibody complex has better stability. After being heated in a water bath at 37° C. for 7 days, its signal retention rate is above 90%. DETAILED DESCRIPTION

[0051] The examples are provided to better illustrate the present invention, but the present invention is not limited to the examples. Therefore, those skilled in the art may make non-essential improvements and adjustments to the implementation scheme according to the above invention content, which still fall within the protection scope of the present invention.

[0052] The terms used herein are only used to describe specific embodiments and are not intended to limit the present disclosure. Unless the context has a significantly different meaning, expressions in the singular include expressions in the plural. As used herein, it should be understood that terms such as "include", "have", "include" are intended to indicate the presence of features, numbers, operations, materials, or combinations. The terms of the present invention are disclosed in the specification, and are not intended to exclude the possibility that one or more other features, numbers, operations, materials, or combinations thereof may exist or may be added. As used herein, " / " may be interpreted as "and" or "or", depending on the circumstances.

[0053] In order to achieve the above object, the present invention can adopt the following technical solutions:

[0054] The present invention provides a method for preparing an acridinium ester-labeled protein complex, which comprises: (1) mixing a protein to be labeled and an acridinium ester group label to obtain a first reaction solution; (2) adding a stop buffer to the first reaction solution to obtain a second reaction solution; (3) purifying the second reaction solution, centrifuging and obtaining a supernatant, which is the acridinium ester-labeled protein complex.

[0055] It should be noted that the purification step in the present invention can quickly remove free acridinium ester and small molecule impurities in the solution, but in the coupling reaction of protein and acridinium ester group markers, a small part of the antibodies will change their conformation due to denaturation, and generally antibodies contain a certain amount of impurity proteins (antibody purity is about 95%). The reactants generated after the reaction of these two substances with acridinium ester group markers have uncertain nonspecific adsorption on the subsequent immune reaction, resulting in poor repeatability and affecting the detection performance of the reagent; for the removal of such substances, because their molecular weight is large, and after protein denaturation and the addition of side reactions, their molecular weight is larger than that of the target product, and they cannot be removed by desalting or dialysis; the invention found that adding centrifugation operation can effectively remove large molecular impurities, reduce the background signal value, and improve repeatability; and will not affect the stability of the acridinium ester labeled protein complex.

[0056] It should also be noted that the principle of acridinium ester luminescence is as follows: in an alkaline H2O2 solution, when the acridinium ester molecule is attacked by hydrogen peroxide ions, the substituents on the acridinium ring can react with C-9 and H2O2 on the acridinium ring to generate unstable ethylene dioxide, which decomposes into CO2 and electronically excited N-methylacridone, which emits photons with a maximum emission wavelength of 430 nm when it returns to the ground state. The characteristics of this type of compound from the perspective of the luminescence mechanism are as follows: (1) in the luminescence reaction, before the formation of the electronically excited intermediate, the non-luminescent substituent part attached to the acridinium ring is separated from the acridinium ring, that is, the non-luminescent part is separated from the luminescent part, so its luminescence efficiency is basically not affected by the structure of the substituent; (2) acridinium ester compounds do not require a catalyst for chemiluminescence and can emit light in a dilute alkaline solution with H2O2. Therefore, it has many advantages in application to chemiluminescence detection, the main advantages of which are: (1) low background luminescence and high signal-to-noise ratio; (2) few interfering factors in the luminescence reaction; (3) rapid and concentrated light release, high luminescence efficiency and high luminescence intensity; (4) easy to bind to proteins and the photon yield does not decrease after binding; (5) the marker is stable (can be stored for several months at 2°C-8°C).

[0057] In some specific examples, the above preparation method satisfies one or more combinations of the following conditions:

[0058] Condition (a): In step (1), the acridinium ester group label is selected from acridinium ester or acridinium sulfonamide; specifically, the acridinium ester group label is all acridinium ester group labels known in the art, preferably acridinium ester or acridinium sulfonamide, more preferably acridinium ester. In the present invention, the protein labeled by it has better luminescence performance;

[0059] Condition (b): In step (1), the protein to be labeled is a labeled protein diluted with a labeling buffer, and the labeling buffer is selected from one or more combinations of a phosphate solution, a carbonate solution, an acetate buffer, and a citrate buffer; more preferably, a citrate buffer. The stability of the acridinium ester labeled protein complex prepared with the citrate buffer is better than that of other labeling buffers; in addition, the phosphate solution, carbonate solution, acetate buffer, and citrate buffer in the present invention can be Na + , K + or NH4 + Of course, it should be understood that some buffer salts usually show alkalinity in aqueous solution due to the hydrolysis of acid ions (such as sodium carbonate or potassium carbonate), that is, the pH value is greater than 7. When used, it is necessary to control the concentration of the corresponding acid and hydrogen ions to control the pH value of the solution or add an appropriate amount of acidic substances to neutralize part of the carbonate ions, thereby lowering the pH value of the solution; the specific method can be selected according to specific needs;

[0060] Condition (c): in step (1), the protein to be labeled is a labeled protein diluted with a labeling buffer, and the concentration of the labeling buffer is 0.01 mol / L-0.03 mol / L, such as 0.015 mol / L, 0.02 mol / L or 0.025 mol / L, etc.; more preferably 0.02 mol / L, at which the labeling efficiency and stability of the protein are better;

[0061] Condition (d): In step (1), the protein to be labeled is a labeled protein diluted with a labeling buffer, and the pH of the labeling buffer is 4-6, such as 4.5, 5 or 5.5, and more preferably 4.5; specifically, acridinium ester group labeling substances (acridinium ester or acridinium sulfonamide) and their complexes are easily hydrolyzed in an environment with a pH value greater than 6, thereby reducing their stability, that is, the higher the pH value, the higher the degree of hydrolysis, and the lower the stability; too low a pH (such as less than 4) will cause acid-insensitive proteins to be inactivated, thereby affecting the labeling efficiency and stability of proteins (such as antibodies), so the present invention preferably prefers 4-6, and more preferably 4.5, at which pH value the labeling efficiency and stability of proteins are better;

[0062] Condition (e): In step (1), the protein to be labeled is total immunoglobulin E antibody (IgE); specifically, the protein to be labeled in the present invention can be all antibodies or antigens or other protein markers known in the present invention, such as total immunoglobulin E antibody (IgE); the present invention can prepare an acridinium ester labeled IgE complex with high sensitivity and good repeatability;

[0063] Condition (f): In step (1), the concentration of the protein to be labeled is 0.5 mg / mL-1.5 mg / mL, such as 0.7 mg / mL, 1 mg / mL or 1.3 mg / mL, etc. Specifically, it should be understood that when the acridinium ester group marker is mixed with the protein to be labeled, the acridinium ester group marker is generally dissolved in an organic solvent (such as DMSO) and then reacted. Based on this, since the acridinium ester is dissolved in the DMSO organic solvent, in order to reduce the effect of DMSO on the activity of the labeled protein, and in order to simply reduce the content of DMSO, excessive dilution leads to a decrease in protein concentration and acridinium ester group marker concentration, thereby causing a decrease in protein labeling efficiency. The preferred concentration of the protein to be labeled in the present invention is 0.5 mg / mL-1.5 mg / mL, more preferably 1 mg / ml, and the labeling efficiency of the protein to be labeled at this concentration is higher; In addition, it should be understood that the concentration of the protein to be labeled is the concentration of the protein in the labeling buffer;

[0064] Condition (g): In step (1), the molar ratio of the protein to be labeled and the acridinium ester group marker is 1: (10-100), such as 1: 20, 1: 30, 1: 40, 1: 50 or 1: 80, etc.; specifically, the molar ratio of the protein to be labeled and the acridinium ester group marker has an effect on the labeling result. The larger the molar ratio of the protein to be labeled and the acridinium ester group marker, the larger the luminescence value. However, after the molar ratio reaches a certain value, the luminescence value will be saturated and will no longer rise; at the same time, the luminescence value of the background will also rise. The molar ratio depends on the project. Different projects have different molar ratios and need to be adjusted according to the project itself. In the present invention, 1: (10-100) is preferred.

[0065] Condition (h): In step (2), the stop buffer is a lysine solution; specifically, the stop buffer in the present invention can be any stop buffer known in the art that can terminate labeling, such as a lysine solution;

[0066] Condition (i): In step (2), the mass of the termination buffer is ≥ 10 times the mass of the protein to be labeled.

[0067] It should be noted that, among the above conditions (a) to (i), one of the conditions can be preferred, or a random combination of any two conditions can be more preferred, or a combination of all the conditions from (a) to (i) can be more preferred, and preferably a combination of all the conditions from (a) to (i) is better than one condition or other combination of conditions. For example, the preparation method in the present invention is more preferably: in step (1), the acridinium ester group marker is acridinium ester; the labeling buffer is citrate buffer, the concentration of the labeling buffer is 0.02 mol / L, and the pH of the labeling buffer is 4.5; the concentration of the protein to be labeled is 1 mg / mL; the molar ratio of the protein to be labeled to the acridinium ester group marker is 1:20; in step (2), the concentration of the lysine solution is ≥10 mg / L.

[0068] In addition, the lysine in the stop solution combines with the unreacted, free acridinium ester in the reaction system to make it fully react and reduce the nonspecific adsorption reaction; the mass of the stop buffer in the present invention is ≥ 10 times the mass of the protein to be labeled in order to enable the unreacted acridinium ester to fully react with it.

[0069] In some specific examples, the above preparation method further satisfies one or more combinations of the following conditions:

[0070] Condition (a): In step (1), the mixed reaction includes: oscillating reaction at 2°C-8°C in the dark for 1.5h-2.5h; specifically, the temperature and time of the mixed reaction will also affect the labeling efficiency of the protein and the intensity of the luminescent signal value. The mixed reaction temperature in the present invention is carried out at a low temperature, and the temperature can preferably be 2°C-8°C, such as 4°C, 6°C or 7°C, and the reaction time can be 1.5h-2.5h, such as 1.8h, 2h or 2.2h, more preferably 2h. The protein labeling efficiency is better and the luminescent value intensity is greater under this reaction temperature and reaction time.

[0071] Condition (b): In step (2), the mixed reaction includes: shaking the reaction at 2°C-8°C in the dark for 20min-30min; specifically, the purpose of the mixed reaction is to terminate the reaction between the acridinium ester group marker and the protein to be labeled, and the termination buffer can remove unreacted acridinium ester and its possible by-products, reduce the reaction background value, and improve the sensitivity of the product; it should be understood that in order to prevent the acridinium ester group marker from decomposing when exposed to light, it is necessary to carry out the reaction under light-proof conditions, and the reaction can be shaken at 2°C-8°C in the dark for 20min-30min, preferably 30min, to quickly terminate the reaction in the shortest time without affecting other performances.

[0072] Condition (c): In step (3), purification includes purification by elution using a desalting column; specifically, if the non-target products generated during the coupling reaction between the acridinium ester group marker and the protein (such as an antibody) cannot be effectively removed, it will lead to high background values, high uncertain nonspecific reactions, poor repeatability and other problems; therefore, purification is required in step (3) to remove free acridinium ester and small molecule impurities, so that the background signal value of the labeled acridinium ester antibody is lower than that of the conventional method, and the repeatability is better; the purification method can be selected from all purification methods known in the art, and in the present invention, desalting column elution purification is preferably used, which is simple and convenient, and has a good purification effect.

[0073] Condition (d): In step (3), purification includes purification by elution using a desalting column, and the eluent is a PBS buffer; specifically, the eluent in the purification by elution using a desalting column can be any eluent known in the art, and in the present invention, PBS buffer can be preferred, which has a better purification effect.

[0074] Condition (e): In step (3), purification includes purification by elution using a desalting column, and the eluent is a PBS buffer having a concentration of 0.01 mol / L-0.03 mol / L, such as 0.015 mol / L, 0.02 mol / L or 0.025 mol / L, etc.; specifically, the PBS buffer is a conventional PBS buffer in the art, and its concentration has an influence on the purification effect. In the present invention, the preferred concentration is 0.01 mol / L-0.03 mol / L, and more preferably 0.02 mol / L, and the PBS buffer at this concentration has a better purification effect.

[0075] Condition (f): In step (3), the centrifugal speed is 14500rpm-15500rpm, such as 14600rpm, 14700rpm, 14800rpm, 15000rpm, 15200rpm or 15400rpm, etc. Specifically, as described above, in the present invention, a further centrifugal operation is required after purification to further remove macromolecular impurities. The centrifugal speed can be selected to be 14500rpm-15500rpm, more preferably 15000rpm. Centrifugation at this centrifugal speed can more effectively remove macromolecular impurities, reduce uncertain nonspecific adsorption reactions, and improve repeatability.

[0076] Condition (g): In step (3), the centrifugation temperature can be 3°C-5°C; similarly, the centrifugation temperature can be selected to be 3°C-5°C, more preferably 4°C, at which temperature, the performance of the labeled protein can be guaranteed not to be affected.

[0077] Condition (h): In step (3), the centrifugation time can be 15 min-25 min. In the present invention, the centrifugation time can be 15 min-25 min, such as 18 min, 20 min, 22 min or 24 min, etc. In the present invention, 20 min is preferred, which can achieve better impurity removal effect in the shortest time.

[0078] It should be noted that, among the above conditions (a) to (h), any one of the conditions can be selected, or two or more of the above conditions can be met at the same time; of course, the most preferred choice is the best choice that satisfies all the above conditions; for example, the preparation method may include: in step (1), the mixing reaction includes: 2°C-8°C light-proof oscillation reaction for 2h; in step (2), the mixing reaction includes: 2°C-8°C light-proof oscillation reaction for 25min; in step (3), using a 0.02mol / L PBS buffer solution for desalting column elution and purification; in step (3), centrifugation at 4°C, 15000rpm for 20min.

[0079] It should also be noted that the preparation method of the present invention is more preferably a combination of the optimal conditions (a) to (h) in the first group of conditions and the optimal conditions (a) to (h) in the second group of conditions, that is, the preparation method of the present invention comprises: in step (1): the acridinium ester group marker is acridinium ester, the labeling buffer is citrate buffer, the concentration of the labeling buffer is 0.02 mol / L, the pH of the labeling buffer is 4.5, the concentration of the protein to be labeled is 1 mg / mL, the molar ratio of the protein to be labeled to the acridinium ester group marker is 1:20, and the mixed reaction comprises: 2°C-8°C light-proof oscillation reaction for 2h; in step (2): the labeling termination buffer is lysine solution, the concentration of the lysine solution is ≥10 mg / L, and the mixed reaction comprises: 2°C-8°C light-proof oscillation reaction for 25min; in step (3), using a 0.02 mol / L PBS buffer for desalting column elution purification; in step (3), centrifugation at 4°C, 15000rpm for 20min.

[0080] In some specific examples, the preparation method further comprises mixing the supernatant with a protein diluent for storage.

[0081] It should be noted that in order to maintain the stability of the prepared acridinium ester-labeled protein complex and protect the protein activity, it is necessary to use a protein diluent for mixing and preservation; the protein diluent in the present invention can be all protein diluents known in the present invention, such as phosphate buffer or glycerol, etc., and also needs to be stored at 20°C (±5°C) away from light. Glycerol is preferred in the present invention, which can be better preserved and can prevent repeated freezing and thawing during use, which affects the activity of the acridinium ester-labeled protein complex.

[0082] In some specific examples, in the above preparation method, the volume proportion of the protein diluent is ≥30%.

[0083] It should be noted that, in the present invention, in order to achieve a better preservation effect, the volume proportion of the protein dilution liquid is ≥30%, such as ≥35%, ≥40% or ≥50%, etc. In the present invention, 30% can be preferred, and a better preservation effect can be achieved with a smaller amount of protein dilution liquid. In addition, the volume proportion of the protein dilution liquid is ≥30% means that the volume of the protein dilution liquid occupies a ratio of ≥30% of the total volume of the protein dilution liquid volume + the supernatant volume; the added protein dilution liquid can be glycerol, which has two main functions: (1) preventing freeze-thaw; (2) adjusting the concentration of the acridinium ester labeled complex solution for subsequent dilution and use.

[0084] The embodiment of the present invention also provides an acridinium ester-labeled protein complex prepared by the preparation method of the present invention.

[0085] The embodiment of the present invention also provides a use of the acridinium ester labeled protein complex of the present invention in detecting antigen / antibody.

[0086] In some specific examples, the above application includes one of the following applications:

[0087] (a) Application of acridinium ester labeled antibodies as labeled antibodies in double antibody sandwich method for antigen determination;

[0088] (b) Application of acridinium ester labeled antigen as competitive antigen in competitive antigen / antibody determination.

[0089] It should be noted that the acridinium ester-labeled protein complex prepared by the preparation method of the present invention can be an acridinium ester-labeled antibody complex or an acridinium ester-labeled antigen complex; it should be understood that when it is an acridinium ester-labeled antibody complex, the specifically bound antigen can be qualitatively or quantitatively tested by the double antibody sandwich method; in addition, when it is an acridinium ester-labeled antigen complex, the specifically bound antigen can be qualitatively or quantitatively tested by the competition method or the unknown same antibody can be quantitatively tested, and the testing methods are all conventional methods in the art.

[0090] In order to better understand the present invention, the content of the present invention is further explained below in conjunction with specific examples, but the content of the present invention is not limited to the following examples.

[0091] 1. Sample preparation

[0092] In the following examples, the method of desalting column elution and purification is shown in Table 1 below.

[0093] Table 1 Desalting column elution and purification method

[0094]

[0095]

[0096] Example 1

[0097] (1) Pipette 0.1 mg of IgE antibody (purchased externally, the same below) and dilute it to 1 mg / mL using labeling buffer (0.02 mol / L, pH 4.5 sodium citrate buffer), and shake thoroughly to mix;

[0098] (2) Add 1.33 μL of acridinium ester solution (10 mmol / L) according to the labeling ratio (the molar ratio of acridinium ester to antibody labeling is 20:1), shake well to mix, and react at 5°C in the dark for 2 hours;

[0099] (3) After the reaction is complete, add 10 μl of 100 mg / mL lysine solution, shake thoroughly to mix, and shake at 5°C in the dark for 25 minutes;

[0100] (4) After the reaction is completed, the product is purified by elution using a desalting column. The eluent is 0.02 mol / L PBS buffer (NaCl 4 g, KCl 0.1 g, Na2HPO4 0.72 g, KH2PO4 0.12 g, then H2O is added to 500 ml and the pH is adjusted to 7.4);

[0101] (5) After elution, centrifuge the mixture using a low-temperature high-speed centrifuge at 4°C with a centrifugal speed of 15,000 rpm for 20 minutes. After centrifugation, take the supernatant, which is 90% of the reaction volume.

[0102] (6) After centrifugation, add 50 μl of glycerol and shake thoroughly to obtain the acridinium ester-labeled IgE antibody complex, which is then stored at -20°C (±5°C) away from light.

[0103] Example 2

[0104] The method of Example 2 is the same as that of Example 1, except that the centrifugal speed in step (5) of Example 2 is 14500 rpm, and the other steps are the same as those of Example 1.

[0105] Example 3

[0106] The method of Example 3 is the same as that of Example 1, except that the centrifugal speed in step (5) of Example 3 is 15500 rpm, and the other steps are the same as those of Example 1.

[0107] Example 4

[0108] The method of Example 4 is the same as that of Example 1, except that the IgE antibody in step (1) of Example 4 is 0.4 mg, the volume of the acridinium ester solution in step (2) is 5.33 μL, and the concentration is 10 mmol / L (the molar ratio of acridinium ester to antibody labeling is 20:1), and the other steps are the same as those of Example 1.

[0109] Example 5

[0110] The method of Example 5 is the same as that of Example 1, except that the labeling buffer used in step (1) of Example 5 is 0.02 mol / L sodium carbonate buffer at pH 4.5, and the other steps are the same as those of Example 1.

[0111] Example 6

[0112] The method of Example 6 is the same as that of Example 1, except that the labeling buffer used in step (1) of Example 6 is 0.02 mol / L sodium citrate buffer at pH 4, and the other steps are the same as those of Example 1.

[0113] Example 7

[0114] The method of Example 7 is the same as that of Example 1, except that the labeling buffer used in step (1) of Example 7 is 0.02 mol / L sodium citrate buffer at pH 6, and the other steps are the same as those of Example 1.

[0115] Comparative Example 1

[0116] The difference between Comparative Example 1 and Example 1 is that in Comparative Example 1, step (5) is omitted and no centrifugation operation is performed.

[0117] Comparative Example 2

[0118] The difference between Comparative Example 2 and Example 5 is that in step (1) of Comparative Example 2, the labeling buffer used is 0.05 mol / L, pH 3 sodium carbonate buffer.

[0119] Comparative Example 3

[0120] The difference between Comparative Example 3 and Example 5 is that in step (1) of Comparative Example 3, the labeling buffer used is 0.05 mol / L, pH 8 sodium carbonate buffer.

[0121] Comparative Example 4

[0122] The difference between Comparative Example 4 and Example 5 is that in step (1) of Comparative Example 4, the labeling buffer used is 0.05 mol / L, pH 9.4 sodium carbonate buffer.

[0123] Comparative Example 5

[0124] The difference between Comparative Example 5 and Example 1 is that in step (2) of Comparative Example 5, the reaction is carried out at 37° C. in the dark for 2 hours.

[0125] 2. Sample Testing

[0126] In the following test, a chemiluminescent immunoassay instrument (iSIA1000) and a double antibody sandwich method were used for luminescence value testing, and the measurement parameters were: one-step method, sample volume 10ul+M (50ul)+R2 (50uL)+R1 (50uL), reaction at 37°C for 20min; wherein, M is an IgE antibody labeled with magnetic particles (purchased externally), R2 is an IgE antibody labeled with acridinium ester (the acridinium ester-labeled IgE antibody complex of the embodiment or comparative example), and R1 is a 10mmol / L PBS buffer solution (purchased externally); in addition, the calibrator is an IgE antigen (mouse monoclonal antibody) (purchased externally).

[0127] (I) Tests of Examples 1 to 3 and Comparative Example 1

[0128] Use zero concentration calibrator, measure 20 times, get the RLU value of 20 measurement results, and calculate the average value and standard deviation (SD), The reaction amount was substituted into the dose-response curve to calculate the corresponding concentration value; in addition, the concentration value of S1 was 1 IU / mL, and the blank limit of the reference Siemens IgE test kit was 1.5 IU / mL. The concentration was calculated by using a two-variable linear equation (y is the luminescence value, x is the concentration value). The results are shown in Table 2.

[0129] Table 2 Blank limit results of Examples 1 to 3 and Comparative Example 1

[0130]

[0131] It can be seen from the data in Table 2 that the background signal value of Comparative Example 1 is much higher than the background signal values ​​of Examples 1, 2 and 3, indicating that the background signal interference of the prepared acridinium ester-labeled IgE antibody complex will increase if the centrifugation operation in step (5) is eliminated.

[0132] The precision of Example 1 and Comparative Example 1 was tested, and the results are shown in Table 3 below.

[0133] Table 3 Precision results of Examples 1 to 3 and Comparative Example 1

[0134]

[0135]

[0136] It can be seen from the data in Table 3 that the precision CV of Comparative Example 1 is also much greater than the precision CV of Examples 1, 2 and 3. Combined with Table 2, it can be explained that the preparation method of the acridinium ester-labeled IgE antibody complex in the present invention can reduce the background of the reagent and improve the sensitivity, while reducing the nonspecific adsorption reaction to achieve better repeatability.

[0137] (II) Tests of Example 1, Examples 4 to 7 and Comparative Examples 2 to 4

[0138] The acridinium ester-labeled IgE antibody complexes prepared in Example 1, Example 4 to Example 7 and Comparative Examples 2 to Comparative Examples 4 were respectively heated in a 37°C water bath for 7 consecutive days and then the luminescence values ​​of the calibrants were measured. The results are shown in Tables 4 to 11 below.

[0139] Table 4 Example 1 Determination of luminescence value of calibration sample after heating in a water bath at 37°C for 7 days

[0140]

[0141] Table 5 Example 4 Determination of luminescence value of calibration sample after heating in a 37°C water bath for 7 days

[0142]

[0143]

[0144] It can be seen from Table 4 and Table 5 that during the operation, only the mass of the acridinium ester-labeled antibody was increased from 0.1 mg (Example 1) to 0.4 mg (Example 4), but the luminescence value remained basically unchanged; This shows that the method for preparing the acridinium ester-labeled antibody complex of the present invention can expand the antibody labeling mass according to experimental needs without affecting the luminescence value.

[0145] Table 6 Example 5 Determination of luminescence value of calibration sample after heating in a 37°C water bath for 7 days

[0146]

[0147] Table 7 Example 6 Determination of luminescence value of calibration sample after heating in a 37°C water bath for 7 days

[0148]

[0149] Table 8 Example 7 Determination of luminescence value of calibration sample after heating in a 37°C water bath for 7 days

[0150]

[0151]

[0152] Table 9 Comparative Example 2 was heated in a water bath at 37°C for 7 days before the luminescence value of the calibration product was measured

[0153]

[0154] Table 10 Comparative Example 3: Luminescence value of the calibration sample after heating in a 37°C water bath for 7 days

[0155]

[0156] Table 11 Comparative Example 4: Luminescence value of the calibration sample after heating in a 37°C water bath for 7 days

[0157]

[0158] It can be seen from Tables 4 and 6 to 11 that during the operation, the labeling buffer was replaced from 0.02 mol / L, pH 4.5 sodium citrate buffer (Example 1) to 0.05 mol / L, pH 9.4 sodium carbonate buffer (Comparative Example 2). The overall luminescence value of the 0-day assay calibrator in Comparative Example 2 is not only much lower than that of Examples 1 to 7, but also significantly reduced after being heated in a 37°C water bath for 7 days, and the overall luminescence value is reduced disproportionately; while the overall signal retention rates of Examples 1 to 7 are all above 85%, indicating that the preparation method of the acridinium ester-labeled antibody complex of the present invention can effectively improve its stability.

[0159] (III) Test of Example 1 and Comparative Example 5

[0160] The luminescence values ​​of the calibration samples of Example 1 and Comparative Example 5 were determined according to the above method. The results are shown in Table 12 below.

[0161] Table 12: Luminescence values ​​of calibration products measured in Example 1 and Comparative Example 5

[0162] Calibrator (IU / mL) Example 1 Comparative Example 5 0 85 97 1 3871 2084 5 18390 12607 20 72823 43747 100 355375 175864 500 1798195 536387 2500 8901066 2011450

[0163] It can be seen from Table 12 that during the operation, the reaction was changed from 8°C in the dark for 2 hours (Example 1) to 37°C in the dark for 2 hours (Comparative Example 5). The overall luminescence value of the calibrator measured in Comparative Example 5 was much lower than that in Example 1; this shows that the preparation method of the acridinium ester-labeled antibody complex in the present invention can improve the antibody labeling efficiency, thereby improving the luminescence value.

[0164] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit it. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the purpose and scope of the technical solution of the present invention, which should be covered by the scope of the claims of the present invention.

Claims

1. A method for preparing an acridinium ester-labeled protein complex, characterized in that: include: (1) mixing the protein to be labeled and the acridinium ester group label to obtain a first reaction solution; (2) adding a stop buffer to the first reaction solution and performing a mixed reaction to obtain a second reaction solution; (3) purifying the second reaction solution and centrifuging to obtain a supernatant, which is the acridinium ester-labeled protein complex.

2. The preparation method according to claim 1, characterized in that The preparation method satisfies one or more of the following conditions: (a) In step (1), the acridinium ester group label is selected from acridinium ester or acridinium sulfonamide; (b) in step (1), the protein to be labeled is a labeled protein diluted with a labeling buffer, and the labeling buffer is selected from one or more combinations of phosphate solution, carbonate solution, acetate buffer, and citrate buffer; (c) In step (1), the protein to be labeled is a labeled protein diluted with a labeling buffer, and the concentration of the labeling buffer is 0.01 mol / L-0.03 mol / L; (d) In step (1), the protein to be labeled is a labeled protein diluted with a labeling buffer, and the pH of the labeling buffer is 4-6; (e) In step (1), the protein to be labeled is total immunoglobulin E antibody; (f) In step (1), the concentration of the protein to be labeled is 0.5 mg / mL to 1.5 mg / mL; (g) In step (1), the molar ratio of the protein to be labeled to the acridinium ester group label is 1:(10-100); (h) In step (2), the stop buffer is a lysine solution; (i) In step (2), the mass of the termination buffer is ≥ 10 times the mass of the protein to be labeled.

3. The preparation method according to claim 2, characterized in that The preparation method satisfies one or more of the following conditions: In step (1), the labeling buffer is a citrate buffer; or In step (1), the concentration of the labeling buffer is 0.02 mol / L; or In step (1), the pH of the labeling buffer is 4.5; or In step (1), the concentration of the protein to be labeled is 1 mg / mL; or In step (1), the molar ratio of the protein to be labeled to the acridinium ester is 1:20; or In step (2), the concentration of the lysine solution is ≥10 mg / L.

4. The preparation method according to any one of claims 1 to 3, characterized in that The preparation method satisfies one or more of the following conditions: (a) In step (1), the mixing reaction comprises: shaking the reaction at 2°C-8°C in the dark for 1.5h-2.5h; (b) In step (2), the mixing reaction comprises: shaking the reaction at 2°C-8°C in the dark for 20 min-30 min; (c) in step (3), purification includes elution purification using a desalting column; (d) In step (3), purification includes elution purification using a desalting column, and the eluent is PBS buffer; (e) In step (3), purification includes elution purification using a desalting column, and the eluent is PBS buffer with a concentration of 0.01 mol / L-0.03 mol / L; (f) In step (3), the centrifugal speed is 14500 rpm-15500 rpm; (g) In step (3), the centrifugation temperature is 3°C-5°C; (h) In step (3), the centrifugation time is 15 min-25 min.

5. The preparation method according to claim 4, characterized in that The preparation method satisfies one or more of the following conditions: In step (1), the mixing reaction includes shaking at 5° C. in the dark for 2 h; or In step (2), the mixing reaction comprises: shaking the reaction at 5° C. in the dark for 25 min; or In step (3), the concentration of PBS buffer is 0.02 mol / L; or In step (3), the centrifugal speed is 15000 rpm; or In step (3), the centrifugation temperature is 4°C; or In step (3), the centrifugation time is 20 min.

6. The preparation method according to claim 1, 2, 3 or 5, characterized in that: The preparation method further comprises mixing the supernatant with a protein diluent for storage.

7. The preparation method according to claim 6, characterized in that The volume proportion of protein diluent is ≥30%.

8. An acridinium ester-labeled protein complex prepared by the preparation method according to any one of claims 1 to 7.

9. Use of the acridinium ester-labeled protein complex according to claim 8 in detecting antigens / antibodies.

10. The use according to claim 9, characterized in that The application includes one of the following: (a) Application of acridinium ester-labeled antibodies as labeled antibodies in double antibody sandwich assays for antigen determination; (b) Application of acridinium ester-labeled antigens as competitive antigens in competitive antigen / antibody determination.

Citation Information

Cited By

  • Acridine sulfonamide derivative, preparation method, application thereof and kit

    CN119775256A

  • Acridine sulfonamide derivative, preparation method, application thereof and kit

    CN119775256B